Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1797787 | 0.80 | SERPINE1 (0.59) | USP2 | |
| SCHEMBL17034648 | 0.80 | MEN1 (0.62) | ALDH1A1HPGDTSHRKMT2APOLB | |
| SCHEMBL17035224 | 0.78 | ALDH1A1 (0.54) | ALDH1A1GAAHPGDTSHRKMT2A | |
| SCHEMBL1015370 | 0.77 | KDM4E (0.60) | ALDH1A1GAAHPGDTSHRKMT2A | |
| SCHEMBL17034756 | 0.77 | MEN1 (0.65) | ALDH1A1GAAHPGDKMT2APOLB | |
| SCHEMBL417874 | 0.75 | RXFP1 (0.54) | ALDH1A1GAAHPGDKMT2AUSP2 | |
| SCHEMBL1015904 | 0.75 | ALDH1A1 (0.54) | ALDH1A1GAAHPGDKMT2AKDM4E | |
| SCHEMBL6510154 | 0.74 | KMT2A (0.63) | ALDH1A1GAAHPGDKMT2AUSP2 | |
| SCHEMBL30044907 | 0.74 | KMT2A (0.63) | ALDH1A1GAAHPGDKMT2AUSP2 | |
| SCHEMBL9674267 | 0.74 | ALDH1A1 (0.65) | ALDH1A1GAAHPGDKMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951806-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20090124620-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | RENASCIENCE CO., LTD. (JP) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124620-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | ALDH1A1 800/4885GAA 721/4885HPGD 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.